NASDAQ$IRON
Disc Medicine Inc · Q2 2024 earnings
Q2 2024 earnings · · Before market open · Investor relations
Briefing
Disc Medicine Inc reported Q2 2024 results with a net loss of $26.4 million and continued advancement of its clinical pipeline.
The company reported a net loss of $26.4 million for the three months ended June 30, 2024, driven by operating expenses of $30.9 million primarily from research and development activities. Cash, cash equivalents, and marketable securities totaled $500.9 million, providing runway into 2027. The company progressed its Phase 2 trials for bitopertin and Phase 1b/2 trials for DISC-0974 while initiating a Phase 1 trial for DISC-3405.
- Net loss increased to $26.4 million from $15.9 million in Q2 2023 due to higher R&D spending.
- R&D expenses rose 94% to $23.5 million, reflecting expanded clinical trial activities.
- Cash and cash equivalents stood at $280.7 million with additional $220.3 million in marketable securities.
- Clinical pipeline advanced with ongoing trials in EPP, XLP, anemia of MF, and PV indications.
Headline financials
Revenue & EPS history
Disc Medicine · Revenue · Quarterly
$0
Forward guidance
The company expects R&D expenses to increase substantially as it advances clinical programs and anticipates continued net losses in the near term.
Tailwinds
- Strong liquidity position supporting operations into 2027
- Multiple ongoing clinical trials across hematologic indications
Headwinds
- No product revenue generated to date
- Increasing operating expenses expected
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
-0.4%
Avg return
Earnings day
-1.7%
Avg return
5 days after
+3.9%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+14.6%
Q3 2021
Best reaction
-12.4%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q4 2026 | +1.3% | -3.8% | -10.2% | |
| Q3 2025 | -1.6% | -2.5% | +5.6% | |
| Q2 2025 | -3.4% | +0.1% | +3.0% | |
| Q1 2025 | +2.3% | +3.8% | +14.1% | |
| Q4 2024 | +0.1% | +1.6% | -3.9% | |
| Q3 2024 | -5.3% | -10.7% | -3.5% | |
| Q1 2024 | +3.5% | +8.5% | +33.3% | |
| Q4 2023 | -8.7% | -9.2% | -56.8% | |
| Q3 2023 | +1.7% | +8.1% | +27.8% | |
| Q2 2023 | +0.3% | +1.9% | -1.2% | |
| Q1 2023 | +0.6% | +1.8% | +47.6% | |
| Q4 2022 | -0.6% | +0.7% | +48.4% | |
| Q3 2022 | -0.6% | -4.7% | -2.4% | |
| Q2 2022 | -12.4% | -10.9% | -31.8% | |
| Q1 2022 | +3.6% | +10.1% | +8.6% | |
| Q4 2021 | -3.2% | -7.7% | -11.0% | |
| Q3 2021 | +14.6% | -5.6% | -12.6% | |
| Q2 2021 | +0.2% | -12.8% | +15.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro